Highlighted PresentationsPharmacologyAntiplatelet

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

solaci
solaci
531
0

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress.

In this case, check the presentation by Dr. Marco Valgimigli, entitled “Is very short DAPT safe in HBR patients undergoing complex PCI”

Marco-valgimigli-solaci-sbhci-2023

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
SOLACI-SBHCI 2023 | Acute pulmonary embolysmworkflow: Patient Screening & Endovascular treatment indications – Dr. João Luiz Frighetto
Next article
Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly
solaci
solaci

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Dr. Omar Tupayachi - 0
Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Dr. Andrés Rodríguez - 0
Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

Dr. Juan Manuel Pérez - 0
The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

Dr. Omar Tupayachi - 0
The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...